163 related articles for article (PubMed ID: 30716713)
1. Development of bioactive gemcitabine-D-Lys
Sayyad N; Vrettos EI; Karampelas T; Chatzigiannis CM; Spyridaki K; Liapakis G; Tamvakopoulos C; Tzakos AG
Eur J Med Chem; 2019 Mar; 166():256-266. PubMed ID: 30716713
[TBL] [Abstract][Full Text] [Related]
2. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer.
Vrettos EI; Karampelas T; Sayyad N; Kougioumtzi A; Syed N; Crook T; Murphy C; Tamvakopoulos C; Tzakos AG
Eur J Med Chem; 2021 Feb; 211():113018. PubMed ID: 33223264
[TBL] [Abstract][Full Text] [Related]
3. GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery.
Karampelas T; Argyros O; Sayyad N; Spyridaki K; Pappas C; Morgan K; Kolios G; Millar RP; Liapakis G; Tzakos AG; Fokas D; Tamvakopoulos C
Bioconjug Chem; 2014 Apr; 25(4):813-23. PubMed ID: 24661240
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy.
Karampelas T; Skavatsou E; Argyros O; Fokas D; Tamvakopoulos C
Mol Pharm; 2017 Mar; 14(3):674-685. PubMed ID: 28099809
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
[TBL] [Abstract][Full Text] [Related]
6. Striking a Balance between Carbonate/Carbamate Linkage Bond- and Reduction-Sensitive Disulfide Bond-Bearing Linker for Tailored Controlled Release: In Situ Covalent-Albumin-Binding Gemcitabine Prodrugs Promote Bioavailability and Tumor Accumulation.
Zhang H; Wang K; Na K; Li D; Li Z; Zhao D; Zhong L; Wang M; Kou L; Luo C; Zhang H; Kan Q; Ding H; He Z; Sun J
J Med Chem; 2018 Jun; 61(11):4904-4917. PubMed ID: 29768008
[TBL] [Abstract][Full Text] [Related]
7. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J
Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328
[TBL] [Abstract][Full Text] [Related]
9. Acid-Triggered Release of Native Gemcitabine Conjugated in Polyketal Nanoparticles for Enhanced Anticancer Therapy.
Zhong H; Mu J; Du Y; Xu Z; Xu Y; Yu N; Zhang S; Guo S
Biomacromolecules; 2020 Feb; 21(2):803-814. PubMed ID: 31995366
[TBL] [Abstract][Full Text] [Related]
10. Implication of linker length on cell cytotoxicity, pharmacokinetic and toxicity profile of gemcitabine-docetaxel combinatorial dual drug conjugate.
Kushwah V; Katiyar SS; Agrawal AK; Saraf I; Singh IP; Lamprou DA; Gupta RC; Jain S
Int J Pharm; 2018 Sep; 548(1):357-374. PubMed ID: 29981409
[TBL] [Abstract][Full Text] [Related]
11. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O
J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
Sun Y; Zhen L; Peng Y; Wang J; Fei F; Aa L; Jiang W; Pei X; Lu L; Liu J; Wang G; Hao K
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 May; 1084():4-13. PubMed ID: 29558739
[TBL] [Abstract][Full Text] [Related]
13. Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation.
Kiew LV; Cheong SK; Sidik K; Chung LY
Int J Pharm; 2010 May; 391(1-2):212-20. PubMed ID: 20214970
[TBL] [Abstract][Full Text] [Related]
14. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Hodge LS; Taub ME; Tracy TS
Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
[TBL] [Abstract][Full Text] [Related]
15. Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.
Tsume Y; Drelich AJ; Smith DE; Amidon GL
Molecules; 2017 Aug; 22(8):. PubMed ID: 28796151
[TBL] [Abstract][Full Text] [Related]
16. Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy.
Zhang C; Pan D; Li J; Hu J; Bains A; Guys N; Zhu H; Li X; Luo K; Gong Q; Gu Z
Acta Biomater; 2017 Jun; 55():153-162. PubMed ID: 28259838
[TBL] [Abstract][Full Text] [Related]
17. The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.
Tsume Y; Incecayir T; Song X; Hilfinger JM; Amidon GL
Eur J Pharm Biopharm; 2014 Apr; 86(3):514-23. PubMed ID: 24361461
[TBL] [Abstract][Full Text] [Related]
18. Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.
Ranđelović I; Schuster S; Kapuvári B; Fossati G; Steinkühler C; Mező G; Tóvári J
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557968
[TBL] [Abstract][Full Text] [Related]
19. Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.
Murányi J; Varga A; Gyulavári P; Pénzes K; Németh CE; Csala M; Pethő L; Csámpai A; Halmos G; Peták I; Vályi-Nagy I
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717403
[TBL] [Abstract][Full Text] [Related]
20. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.
Song X; Lorenzi PL; Landowski CP; Vig BS; Hilfinger JM; Amidon GL
Mol Pharm; 2005; 2(2):157-67. PubMed ID: 15804190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]